600422 昆药集团
2026/06 - 中期
人民幣(K¥)
与去年同期
比较
2025/12
人民幣(K¥)
2024/12
人民幣(K¥)
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
营业总收入1,643,045-50.97%6,575,2148,401,4478,430,1778,282,063
减:营业总成本1,961,201-36.74%6,335,5617,550,2047,663,8507,835,515
    其中:营业成本1,326,466-34.20%4,042,2854,750,1974,500,8264,843,690
               财务费用20,566-11.00%43,25213,9881,53838,309
               资产减值损失(45,418)855.57%(31,590)(21,955)(66,537)(67,592)
公允价值变动收益8-99.43%108,9146,9161,02610,673
投资收益(6,373)817.53%62,01114,93317,3125,985
    其中:对联营企业和合营企业的投资收益(9,101)-35,324.84%54,361(502)(186)(255)
营业利润(390,852)-230.37%448,508927,547789,670497,148
利润总额(395,677)-232.36%473,558934,570786,376477,287
减:所得税费用(25,982)-153.00%54,505183,350143,70391,827
净利润(369,695)-247.92%419,053751,221642,674385,459
减:非控股权益(5,747)-111.15%69,112103,139101,9632,276
股东净利润(363,948)-283.48%349,941648,081540,711383,184

市场价值指针
每股收益 (元) *-0.480-284.62%0.4600.8600.7100.510
每股派息 (元) *----0.1800.3000.2000.160
每股净资产 (元) *6.426-6.94%7.0846.9406.9896.572
审计意见 #--标准无保留意见标准无保留意见标准无保留意见标准无保留意见
回页顶
备注: *未调整数据
#只提供简体内容